WHO List of Priority Medical Devices for Cancer Management


Book Description

This is the model list and clearing house of appropriate, basic, and priority medical devices based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring, and end of life care. This publication addresses medical devices that can be used for the management of cancer and specifically describes medical devices for six types of cancer: breast, cervical, colorectal, leukemia, lung, and prostate. This book is intended for ministries of health, public health planners, health technology managers, disease management, researchers, policy makers, funding, and procurement agencies and support and advocacy groups for cancer patients.




Translational Research in Breast Cancer


Book Description

This book describes recent advances in translational research in breast cancer and presents emerging applications of this research that promise to have meaningful impacts on diagnosis and treatment. It introduces ideas and materials derived from the clinic that have been brought to "the bench" for basic research, as well as findings that have been applied back to "the bedside". Detailed attention is devoted to breast cancer biology and cell signaling pathways and to cancer stem cell and tumor heterogeneity in breast cancer. Various patient-derived research models are discussed, and a further focus is the role of biomarkers in precision medicine for breast cancer patients. Next-generation clinical research receives detailed attention, addressing the increasingly important role of big data in breast cancer research and a wide range of other emerging developments. An entire section is also devoted to the management of women with high-risk breast cancer. Translational Research in Breast Cancer will help clinicians and scientists to optimize their collaboration in order to achieve the common goal of conquering breast cancer.




Tamoxifen


Book Description

Tamoxifen is a pioneering medicine for the treatment and prevention of breast cancer. It is the first drug targeted therapy in cancer to be successful. Tamoxifen targets the tumor estrogen receptor. The therapy is known to have saved the lives of millions of women over the past 40 years. This monograph, written by V. Craig Jordan - known as the “father of tamoxifen” - and his Tamoxifen Team at the Georgetown University Washington DC, illustrates the journey of this milestone in medicine. It includes a personal interview with V. Craig Jordan about his four decades of discovery in breast cancer research and treatment. V. Craig Jordan was there for the birth of tamoxifen as he is credited for reinventing a “failed morning after contraceptive” to become the “gold standard” for the treatment of breast cancer. He contributed to every aspect of tamoxifen application in therapeutics and all aspects of tamoxifen’s pharmacology. He discovered the selective estrogen receptor modulators (SERMs) and explored the new biology of estrogen-induced apoptosis.




Early Detection of Breast Cancer


Book Description

The enormous expansion seen over the last decade in the mammo graphic detection of breast cancer lesions, especially the use of screen ing procedures for the early detection of clinically unsuspected tumors, has made it necessary to summarize the experience made by various centers in the world. The 2nd International Copenhagen Symposium on Detection of Breast Cancer afforded an opportunity of gathering scientists from all over the world to discuss the various problems of early breast cancer detection with special reference to screening procedures. This book forms a synthesis of the information presented by leading scientists from many of the world's mammo graphic centers, particularly those in Sweden and the USA. Hence, the reader will have the opportunity to study the outstanding work carried out by various institutes and centers of breast cancer screening. It is our sincere hope that a study of this volume will encourage other scientists to join in the work on screening procedures. S. Brunner B. Langfeldt P. E. Andersen Contents S. A. Feig: 1 Hypothetical Breast Cancer Risk from Mammography S. A. Feig: Benefits and Risks of Mammography 11 R. L. Egan and M. B. McSweeney: Multicentric Breast Carcinoma . . . . . . . . . . . . . . . . . . . . . . . . 28 M. B. McSweeney and R. L. Egan: Breast Cancer in the Younger Patient: A Preliminary Report 36 M. B. McSweeney and R. L. Egan: Bilateral Breast Carcinoma . . . . . . . . . . . . . . . . . . . . . . . . . . . ' 41 N. Bjurstam: The Radiographic Appearance of Normal and Metastatic Axillary Lymph Nodes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49 M. Moskowitz, S. A. Feig, C. Cole-Beuglet, S. H.




Targeted Therapies in Breast Cancer


Book Description

This new volume updates the reader on selected areas of targeted therapy in breast cancer, with special emphasis on chemoprevention strategies, drug resistance, biomarkers, combination chemotherapy, angiogenesis inhibition and pharmacogenomics in the context of clinical efficacy. This selected review of targeted therapies will guide the reader on effective treatment as part of an integrated programme of patient management.




HER2-Positive Breast Cancer


Book Description

Get a quick, expert overview of clinically-focused topics and guidelines that are relevant to testing for HER2, which contributes to approximately 25% of breast cancers today. This concise resource by Drs. Sara Hurvitz, and Kelly McCann consolidates today's available information on this growing topic into one convenient resource, making it an ideal, easy-to-digest reference for practicing and trainee oncologists. - Covers the diagnosis, treatments and targeted therapies, and management of breast cancers that are HER2-positive. - Contains sections on background and testing, advanced disease, therapeutics, and toxicity considerations. - Includes a timely section on innovative future therapies.




Toxicities of Radiation Treatment for Breast Cancer


Book Description

This book is a comprehensive guide to breast toxicity. Adjuvant radiation remains standard for a majority of women who undergo breast-conserving surgery for breast cancer, and indications for post-mastectomy and regional lymph node irradiation have also broadened with recent publications. At the same time, locoregional recurrence has declined and survival has improved in recent decades. In the current era of excellent breast cancer outcomes, then, considering the balance between toxicity and outcomes becomes paramount. Several recent editorials recommend considering toxicity against the potential benefit of adjuvant radiation in tailoring radiation decisions for individual patients. Thus, a clear understanding of the potential toxicities of adjuvant radiation for breast cancer is critical to optimizing outcomes in modern breast cancer management. Here, authors have collected recent data focused on toxicity of treatment that provide an opportunity for improving this optimization. Chapters cover both acute and late toxicity of radiation for breast cancer, including tailored risk assessment for each of these potential toxicities, considerations for including risk of toxicity in management decisions, and toxicity management strategies. This is an ideal guide for radiation oncologists, residents, and oncologists seeking to optimize care for their patients.




Breast Cancer Prevention and Treatment


Book Description

Uniquely designed for oncologists and general practitioners, this book offers clinicians comprehensive guidelines when dealing with women at high risk for breast cancer. Written by experts in the field on the cutting edge of this research, the following questions will be answered for the reader by the end of the book: · Who is at elevated risk for breast cancer? · Who should be genetically screened? · When and how often should we obtain imaging? · What type of imaging is adequate? · What medications are available for prevention? · When is surgical intervention appropriate? · What lifestyle changes should be implemented to prevent this disaster? With one in eight women likely to contract breast cancer in her lifetime, the significance of identifying and managing the high-risk patient is evident. Breakthroughs in the identification of genes associated with breast carcinoma, particularly BRCA1 and 2, as well as other risk factors, influence not only how patients are screened, but also how they are treated. Breast Cancer Prevention and Treatment provides a guided approach to prevention of breast cancer in women at elevated risk for this malignancy.







Managing the Oral Effects of Cancer Treatment


Book Description

Guides everyone who cares for patients with cancer through the management of oral health problems.